close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Pharming Group NV
Search

Pharming Group NV

Avatud

1.521 -1.36

Hinna uuendus 14. jaan 2026, 13:10 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.5

Max

1.545

Põhinäitajad

By Trading Economics

Sissetulek

2.9M

7.5M

Müük

4.1M

97M

Aktsiakasum

0.009

Kasumimarginaal

7.758

Töötajad

404

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

2. apr 2026

Turustatistika

By TradingEconomics

Turukapital

-2M

995M

Eelmine avamishind

2.88

Eelmine sulgemishind

1.521

Pharming Group NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. jaan 2026, 19:05 UTC

Suurimad hinnamuutused turgudel

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

DJ

Loe

13. jaan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

DJ

Loe

13. jaan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

13. jaan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

DJ

Loe

13. jaan 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

DJ

Loe

13. jaan 2026, 23:10 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

DJ

Loe

13. jaan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

DJ

Loe

13. jaan 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

DJ

Loe

13. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

DJ

Loe

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

DJ

Loe

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

DJ

Loe

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

DJ

Loe

13. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

VERSANT Completes Acquisition Of Free TV Networks >VSNT

DJ

Loe

13. jaan 2026, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

DJ

Loe

13. jaan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

DJ

Loe

13. jaan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

DJ

Loe

13. jaan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

DJ

Loe

13. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

DJ

Loe

13. jaan 2026, 19:03 UTC

Tulu

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

DJ

Loe

13. jaan 2026, 18:50 UTC

Tulu

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

DJ

Loe

13. jaan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

DJ

Loe

13. jaan 2026, 17:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

DJ

Loe

13. jaan 2026, 17:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

DJ

Loe

13. jaan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

DJ

Loe

13. jaan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

DJ

Loe

13. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

13. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

13. jaan 2026, 17:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

DJ

Loe

13. jaan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

DJ

Loe

13. jaan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

DJ

Loe

Pharming Group NV Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Põhineb 0 analüütiku instrumendi Pharming Group NV aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat